Lupei Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lupei Du has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Minyong Li
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China; Key Laboratory of Tropical Biological Resources (MOE), School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan 570228, China
48 shared publications Xiaojun Qin
Pharmaceutical College, Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Key Laboratory of Micro-Nanoscale Bioanalysis and Drug Screening of Guangxi Education Department, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi 530021, China
14 shared publicationsGaopan Dong
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
10 shared publicationsXingye Yang
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
10 shared publicationsZhao Ma
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
10 shared publicationsZhenzhen Li
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
9 shared publications
Latest Publications
- 29 June 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 317, 119107
Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders
- 29 June 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 317, 119107
Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders
- 3 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21520-21533
Optical Control of Leukotriene A4 Hydrolase Using Photoswitchable Inhibitors
Leukotriene A4 hydrolase (LTA4H) is a prominent therapeutic target for leukotriene-associated inflammatory diseases, including cardiovascular diseases, asthma, and various tumor types. Using light to modulate LTA4H activity precisely is a leading approach to intervening in these inflammatory diseases. In this study, we utilized the azobenzene moiety to replace the diphenyl ether scaffold in LYS006, an LTA4H inhibitor developed by Novartis. We synthesized ten azobenzene-based photoswitchable LTA4H inhibitors with suitable photochemical properties. According to the enzymatic inhibitory assay, piLTA4H-1 was screened out since it significantly increases (∼150-fold) in inhibiting LTA4H when the condition changes from dark to 365 nm light exposure. Photoswitchable piLTA4H-1 could effectively modulate the eicosanoid release in mouse whole blood and enable the smart and effective intervention of arachidonic acid-induced ear dermatitis in mice. Optical control of LTA4H with piLTA4H-1 represents a promising strategy for inflammation intervention both in vitro and in vivo.
- 3 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21520-21533
Optical Control of Leukotriene A4 Hydrolase Using Photoswitchable Inhibitors
Leukotriene A4 hydrolase (LTA4H) is a prominent therapeutic target for leukotriene-associated inflammatory diseases, including cardiovascular diseases, asthma, and various tumor types. Using light to modulate LTA4H activity precisely is a leading approach to intervening in these inflammatory diseases. In this study, we utilized the azobenzene moiety to replace the diphenyl ether scaffold in LYS006, an LTA4H inhibitor developed by Novartis. We synthesized ten azobenzene-based photoswitchable LTA4H inhibitors with suitable photochemical properties. According to the enzymatic inhibitory assay, piLTA4H-1 was screened out since it significantly increases (∼150-fold) in inhibiting LTA4H when the condition changes from dark to 365 nm light exposure. Photoswitchable piLTA4H-1 could effectively modulate the eicosanoid release in mouse whole blood and enable the smart and effective intervention of arachidonic acid-induced ear dermatitis in mice. Optical control of LTA4H with piLTA4H-1 represents a promising strategy for inflammation intervention both in vitro and in vivo.
- Open Access
- 7 June 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 81, 1005-1021
Development and characterization of endolysosomal trafficking targeting chimera degraders of α1A-adrenergic receptor
- 7 June 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 81, 1005-1021
Open AccessDevelopment and characterization of endolysosomal trafficking targeting chimera degraders of α1A-adrenergic receptor
- 5 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 12143-12154
Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging
SHP2 protein, a nonreceptor type protein tyrosine phosphatase, is a crucial signal transduction regulator. It interacts with key signaling molecules in the RAS/ERK and PD-1/PD-L1 pathways and significantly affects cell proliferation, differentiation, and immune regulation. It is a promising target for cancer therapy and plays a role in the progression of various tumors. In this study, we report the design and synthesis of near-infrared (NIR) small-molecule fluorescent probes for the recognition and labeling of SHP2. These probes exhibited superior optical properties, strong target affinity, and high selectivity for SHP2. The top-performing probe, SHP-PP2, demonstrated an IC50 of 0.86 μmol/L against SHP2 activity and a Kd of 0.91 μmol/L in binding studies, indicating its potent inhibitory effect and binding affinity. In summary, these probes can effectively enable the visualization of SHP2 in living cells and tissue sections, thereby facilitating further research on SHP2.
- 5 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 12143-12154
Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging
SHP2 protein, a nonreceptor type protein tyrosine phosphatase, is a crucial signal transduction regulator. It interacts with key signaling molecules in the RAS/ERK and PD-1/PD-L1 pathways and significantly affects cell proliferation, differentiation, and immune regulation. It is a promising target for cancer therapy and plays a role in the progression of various tumors. In this study, we report the design and synthesis of near-infrared (NIR) small-molecule fluorescent probes for the recognition and labeling of SHP2. These probes exhibited superior optical properties, strong target affinity, and high selectivity for SHP2. The top-performing probe, SHP-PP2, demonstrated an IC50 of 0.86 μmol/L against SHP2 activity and a Kd of 0.91 μmol/L in binding studies, indicating its potent inhibitory effect and binding affinity. In summary, these probes can effectively enable the visualization of SHP2 in living cells and tissue sections, thereby facilitating further research on SHP2.
- 10 May 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (6) , 1839-1846
Deuteration-Driven Photopharmacology: Deuterium-Labeled AzoCholine for Controlling Alpha 7 Nicotinic Acetylcholine Receptors
Photopharmacology is a powerful approach to investigate biological processes and overcomes the common therapeutic challenges in drug development. Enhancing the photopharmacology properties of photoswitches contributes to extend their applications. Deuteration, a tiny structural modification, makes it possible to improve the photopharmacology and photophysical properties of prototype compounds, avoiding extra complex chemical changes or constructing multicomponent systems. In this work, we developed a series of D-labeled azobenzenes to expand the azobenzene photoswitchable library and introduced the D-labeled azobenzene unit into the photoagonist of α7 nicotinic acetylcholine receptors (α7 nAChRs) to investigate the effects of deuteration in photopharmacology. Spectral data indicated that deuteration maintained most of the photophysical properties of azobenzenes. The D-labeled photoagonist exhibited good control of the activity of α7 nAChRs than the prototype photoagonist. These results confirmed that deuteration is a promising strategy to improve the photopharmacological properties.
- 10 May 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (6) , 1839-1846
Deuteration-Driven Photopharmacology: Deuterium-Labeled AzoCholine for Controlling Alpha 7 Nicotinic Acetylcholine Receptors
Photopharmacology is a powerful approach to investigate biological processes and overcomes the common therapeutic challenges in drug development. Enhancing the photopharmacology properties of photoswitches contributes to extend their applications. Deuteration, a tiny structural modification, makes it possible to improve the photopharmacology and photophysical properties of prototype compounds, avoiding extra complex chemical changes or constructing multicomponent systems. In this work, we developed a series of D-labeled azobenzenes to expand the azobenzene photoswitchable library and introduced the D-labeled azobenzene unit into the photoagonist of α7 nicotinic acetylcholine receptors (α7 nAChRs) to investigate the effects of deuteration in photopharmacology. Spectral data indicated that deuteration maintained most of the photophysical properties of azobenzenes. The D-labeled photoagonist exhibited good control of the activity of α7 nAChRs than the prototype photoagonist. These results confirmed that deuteration is a promising strategy to improve the photopharmacological properties.
- 12 March 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (4) , 1178-1190
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
A promising alternative for cancer treatment involves targeted inhibition of the epigenetic regulator bromodomain-containing protein 4 (BRD4); however, available BRD4 inhibitors are constrained by their potency, oral bioavailability, and cytotoxicity. Herein, to overcome the drawback of the translational BRD4 inhibitors, we describe a novel BRD4-p53 inhibitor, SDU-071, which suppresses BRD4 interaction with the p53 tumor suppressor and its biological activity in MDA-MB-231 triple-negative breast cancer (TNBC) cells in vitro and in vivo. This novel small-molecule BRD4-p53 inhibitor suppresses cell proliferation, migration, and invasion by downregulating the expression of BRD4-targeted genes, such as c-Myc and Mucin 5AC, and inducing cell cycle arrest and apoptosis, as demonstrated in cultured MDA-MB-231 TNBC cells. Its antitumor activity is illustrated in an orthotopic mouse xenograft mammary tumor model. Overall, our results show that SDU-071 is a viable option for potentially treating TNBC as a new BRD4-p53 inhibitor.
- 12 March 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (4) , 1178-1190
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
A promising alternative for cancer treatment involves targeted inhibition of the epigenetic regulator bromodomain-containing protein 4 (BRD4); however, available BRD4 inhibitors are constrained by their potency, oral bioavailability, and cytotoxicity. Herein, to overcome the drawback of the translational BRD4 inhibitors, we describe a novel BRD4-p53 inhibitor, SDU-071, which suppresses BRD4 interaction with the p53 tumor suppressor and its biological activity in MDA-MB-231 triple-negative breast cancer (TNBC) cells in vitro and in vivo. This novel small-molecule BRD4-p53 inhibitor suppresses cell proliferation, migration, and invasion by downregulating the expression of BRD4-targeted genes, such as c-Myc and Mucin 5AC, and inducing cell cycle arrest and apoptosis, as demonstrated in cultured MDA-MB-231 TNBC cells. Its antitumor activity is illustrated in an orthotopic mouse xenograft mammary tumor model. Overall, our results show that SDU-071 is a viable option for potentially treating TNBC as a new BRD4-p53 inhibitor.
- 17 July 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (9) , 103716
Degradation of extracellular and membrane proteins in targeted therapy: Status quo and quo vadis
- 17 July 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (9) , 103716
Degradation of extracellular and membrane proteins in targeted therapy: Status quo and quo vadis
- 20 June 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (25) , 14165-14166
Correction to “Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3”
- 20 June 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (25) , 14165-14166
Correction to “Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3”
- 26 January 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (5) , 2848-2856
Development and Characterization of a Highly Selective Turn-On Fluorescent Ligand for β3-Adrenergic Receptor
For the precise visualization of GPCR, subtype selectivity of turn-on fluorescent ligands is of major relevance. Although there are many thriving β-adrenergic receptors (β-ARs) probes, none of them are selective to the β3-subtype, which severely limits the development of β3-AR investigations. Using a polyethylene glycol (PEG) chain to conjugate the Py-5 fluorophore with mirabegron, we present here a highly selective fluorescent ligand, H2, for β3-AR. It was established by the radioligand and NanoLuc-based bioluminescence resonance energy transfer (NanoBRET) binding experiments that molecule H2 has a substantially higher affinity for β3-AR than the other two subtypes (1/3, 45-fold; 2/3, 16-fold). More crucially, when molecule H2 was incubated with β3-AR, the turn-on fluorescent signals could be quickly released. The subsequent investigations, which included cell imaging, tissue imaging, and flow-cytometry analysis, proved that molecule H2 may make it possible to quickly and accurately fluorescently identify β3-AR at different levels. We offer a prospective fluorescent turn-on ligand with exceptional selectivity for β3-AR as a result of our combined efforts.
- 26 January 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (5) , 2848-2856
Development and Characterization of a Highly Selective Turn-On Fluorescent Ligand for β3-Adrenergic Receptor
For the precise visualization of GPCR, subtype selectivity of turn-on fluorescent ligands is of major relevance. Although there are many thriving β-adrenergic receptors (β-ARs) probes, none of them are selective to the β3-subtype, which severely limits the development of β3-AR investigations. Using a polyethylene glycol (PEG) chain to conjugate the Py-5 fluorophore with mirabegron, we present here a highly selective fluorescent ligand, H2, for β3-AR. It was established by the radioligand and NanoLuc-based bioluminescence resonance energy transfer (NanoBRET) binding experiments that molecule H2 has a substantially higher affinity for β3-AR than the other two subtypes (1/3, 45-fold; 2/3, 16-fold). More crucially, when molecule H2 was incubated with β3-AR, the turn-on fluorescent signals could be quickly released. The subsequent investigations, which included cell imaging, tissue imaging, and flow-cytometry analysis, proved that molecule H2 may make it possible to quickly and accurately fluorescently identify β3-AR at different levels. We offer a prospective fluorescent turn-on ligand with exceptional selectivity for β3-AR as a result of our combined efforts.
- 27 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 733-751
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
Targeted protein degradation (TPD) strategies open up new avenues for therapeutics and provide powerful tools for biological inquiry. Herein, we present a brand-new approach, termed heat shock protein 90 (HSP90)-mediated targeting chimeras (HEMTACs), to induce intracellular protein degradation by bridging a target protein to HSP90 to drive the downregulation of proteins. We successfully showcase HEMTACs for cyclin-dependent kinase 4 and 6 (CDK4/6) by using a flexible linker to connect the targeting warhead of CDK4/6 with the HSP90 ligand. Overall, our study delivers a series of evidence that HEMTACs can serve as a valuable addition to TPD strategies, most prominently proteolysis-targeting chimera technology.
- 27 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 733-751
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
Targeted protein degradation (TPD) strategies open up new avenues for therapeutics and provide powerful tools for biological inquiry. Herein, we present a brand-new approach, termed heat shock protein 90 (HSP90)-mediated targeting chimeras (HEMTACs), to induce intracellular protein degradation by bridging a target protein to HSP90 to drive the downregulation of proteins. We successfully showcase HEMTACs for cyclin-dependent kinase 4 and 6 (CDK4/6) by using a flexible linker to connect the targeting warhead of CDK4/6 with the HSP90 ligand. Overall, our study delivers a series of evidence that HEMTACs can serve as a valuable addition to TPD strategies, most prominently proteolysis-targeting chimera technology.